IL17A and psoriatic arthritis: As shown in Fig. (2) and Supplementary Table S1, most patients were taking standard dosing of anti-tumor necrosis factors (anti-TNFs) (n = 45, 75%), followed by Janus Kinase inhibitors (JAKi) (n = 6, 10%), interleukin-17 inhibitors (IL-17i) (n = 5, 8.3%) and others (n = 4, 6.6%) (i.e., IL12/23 inhibitors and Abatacept in patients with co-existing psoriatic arthritis).